Burkitt lymphoma
C López, B Burkhardt, JKC Chan, L Leoncini… - Nature Reviews …, 2022 - nature.com
Burkitt lymphoma (BL) is an aggressive form of B cell lymphoma that can affect children and
adults. The study of BL led to the identification of the first recurrent chromosomal aberration …
adults. The study of BL led to the identification of the first recurrent chromosomal aberration …
Science and health for all children with cancer
Each year~ 429,000 children and adolescents aged 0 to 19 years are expected to develop
cancer. Five-year survival rates exceed 80% for the 45,000 children with cancer in high …
cancer. Five-year survival rates exceed 80% for the 45,000 children with cancer in high …
Rituximab for high-risk, mature B-cell non-Hodgkin's lymphoma in children
V Minard-Colin, A Aupérin, M Pillon… - … England Journal of …, 2020 - Mass Medical Soc
Background Rituximab added to chemotherapy prolongs survival among adults with B-cell
cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non …
cancer. Data on its efficacy and safety in children with high-grade, mature B-cell non …
Positron emission tomography–guided therapy of aggressive non-Hodgkin lymphomas (PETAL): a multicenter, randomized phase III trial
U Dührsen, S Müller, B Hertenstein… - Journal of Clinical …, 2018 - ascopubs.org
Purpose Interim positron emission tomography (PET) using the tracer,[18F]
fluorodeoxyglucose, may predict outcomes in patients with aggressive non-Hodgkin …
fluorodeoxyglucose, may predict outcomes in patients with aggressive non-Hodgkin …
Acute lymphoblastic leukaemia
CH Pui, LL Robison, AT Look - The Lancet, 2008 - thelancet.com
Acute lymphoblastic leukaemia, a malignant disorder of lymphoid progenitor cells, affects
both children and adults, with peak prevalence between the ages of 2 and 5 years. Steady …
both children and adults, with peak prevalence between the ages of 2 and 5 years. Steady …
Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead
V Minard-Colin, L Brugières, A Reiter… - Journal of Clinical …, 2015 - ascopubs.org
Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even
higher incidence in adolescents, and is primarily represented by only a few histologic …
higher incidence in adolescents, and is primarily represented by only a few histologic …
Clinical relevance of molecular characteristics in Burkitt lymphoma differs according to age
B Burkhardt, U Michgehl, J Rohde, T Erdmann… - Nature …, 2022 - nature.com
While survival has improved for Burkitt lymphoma patients, potential differences in outcome
between pediatric and adult patients remain unclear. In both age groups, survival remains …
between pediatric and adult patients remain unclear. In both age groups, survival remains …
Revised international pediatric non-Hodgkin lymphoma staging system
A Rosolen, SL Perkins, CR Pinkerton… - Journal of clinical …, 2015 - ascopubs.org
Purpose Treatment and prognosis of pediatric non-Hodgkin lymphoma (NHL) have
improved dramatically in the last 30 years. However, the St Jude NHL staging classification …
improved dramatically in the last 30 years. However, the St Jude NHL staging classification …
Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects
LR Treviño, N Shimasaki, W Yang… - Journal of Clinical …, 2009 - ascopubs.org
Purpose Methotrexate plasma concentration is related to its clinical effects. Our aim was to
identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in …
identify the genetic basis of interindividual variability in methotrexate pharmacokinetics in …
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce …
C Patte, A Auperin, M Gerrard, J Michon, R Pinkerton… - Blood, 2007 - ashpublications.org
A previous study (LMB89) of the French Society of Pediatric Oncology for childhood mature
B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for …
B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for …